Atorvastatin plus omega-3 for artery plaque in type 2 diabetes
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial studies whether a combination of atorvastatin and omega-3 can reduce signs of artery plaque in people with type 2 diabetes and “mixed” cholesterol problems. It’s focused on people who don’t have symptoms from plaque yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 20 or older, and you have type 2 diabetes
- Your diabetes blood test (HbA1c) is between 6.0% and 10.0%
- Your cholesterol pattern fits “mixed dyslipidemia” (high triglycerides, low HDL, and higher LDL) while taking a moderate-dose statin
- Ultrasound shows plaque thickening in the neck artery (carotid intima-media thickness of at least 1.0 mm)
- You have no history of chest pain (angina), heart attack, or stroke, and you aren’t currently having those symptoms
- Your kidney and liver tests are not too abnormal (creatinine ≤1.8; eGFR ≥30; AST/ALT not over 120/120)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether choline fenofibrate can improve blood vessel plaque (carotid artery plaque) in people with type 2 diabetes and mixed cholesterol problems. It aims to see if the medicine can make carotid plaque thinner or otherwise healthier while keeping safety in mind.
This trial tests if pitavastatin alone or with ezetimibe affects blood sugar differently than atorvastatin in people who have heart or blood vessel disease and metabolic syndrome but do not have diabetes.
This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.
This trial tests a combination pill of two cholesterol-lowering medicines (pitavastatin and ezetimibe) in adults who have been taking either atorvastatin or rosuvastatin for at least 3 months. It aims to see if switching to this new combination is safe and effective.
This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.
This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.
Hear when a new Atherosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.